Treatment using PDE5 inhibitors also improves systemic vasorelaxation capacity, and preclinical evidence from DMD murine models demonstrates the ability of PDE5 inhibitors to prevent skeletal and cardiac muscle damage and even reverse the functional parameters associated with established cardiomyopathy. This evidence concerns the gene PDE5A and cardiomyopathy.